On the afternoon of November 28, 2024, with the countdown on the large screen starting, the VIQU Nuclear Medicine CXO Alliance set sail brilliantly in Shanghai, marking a successful opening ceremony. The alliance was jointly initiated by DeepView Pharmaceuticals, Innovo Therapeutics, Quarkmed, and United Imaging High-Tech Research Institute, aiming to create new models and benchmarks for nuclear medicine CRO services through complementary advantages and efficient cooperation, pooling innovative forces in nuclear medicine technology to empower nuclear medicine innovation.

 

The launch ceremony was hosted by President Li Zheng from Beijing United Imaging Intelligent Imaging Technology Research Institute. Director Yang Zhi from Peking University Cancer Hospital extended sincere congratulations to the Alliance on behalf of the Chinese Nuclear Society, expressing his earnest hope that the VIQU Alliance will fully leverage its role as a bridge and link to promote in-depth cooperation among industry, academia, research, and application in nuclear medicine. Meanwhile, several industry experts and scholars, including Researcher Xu Wanbang from Guangdong Institute for Drug Control, Researcher Ji Bin from Fudan University School of Pharmacy, Dr. Zeng Dexing, President of ADVANCED MOLECULAR TARGETING SCIENCE, and Dr. Wang Xiaolei, Senior Director of Chengdu Neurayt, all extended sincere congratulations on the establishment of the Alliance.

 

The Inauguration Ceremony of VIQU Nuclear Medicine CXO Alliance

 

President Li Zheng of Beijing United Imaging Intelligence Medical Imaging Technology Research Institute served as the host of the ceremony.

 

Director Yang Zhi from Peking University Cancer Hospital delivered a speech on behalf of the Chinese Nuclear Society.

 

Address by Research Fellow Xu Wanbang from Guangdong Institute for Drug Control

Address by Research Fellow Ji Bin at School of Pharmacy, Fudan University

Dr. Zeng Dexing, President of Advanced Molecular Targeting Science, delivers a speech.

Dr. Wang Xiaolei, Senior Director of Chengdu Newlight, Delivers a Speech

Comprehensive Exploration: In-depth Analysis Forum on Nuclear Medicine R&D

 

As co-organizers of RDS2024, the four alliance members jointly hosted the conference sub-forum - "End-to-End Exploration: In-depth Analysis of Radiopharmaceutical Development". The forum invited top experts and scholars from domestic radiopharmaceutical research and development fields, with presentation topics covering the entire development cycle including CMC, preclinical studies, clinical trials, quality supervision, and medical imaging. It provided a platform for in-depth dialogue and idea exchange among industry professionals, facilitating the dissemination of cutting-edge concepts and advanced technologies in radiopharmaceutical development.

Dr. Zhou Yun, Chief Scientific Officer of United Imaging Research Institute, served as the forum moderator.

Wen Kai, Manager of R&D Department at Atom High-Tech, presented a thematic sharing on "Current Industry Status and Future Prospects of Radiopharmaceuticals".

Dr. Li Zheng, Technical Director of Deepview Pharmaceuticals, presented a thematic sharing on "Key Considerations in Radiopharmaceutical CMC Development".

Wang Xijie, Senior Vice President of Yinnuosi Toxicology Division, presented a thematic sharing on "Non-clinical Evaluation Strategies for Radiopharmaceuticals".

Xu Wanbang, Research Fellow from Guangdong Institute for Drug Control, presented a topic on "Quality Control Laboratory Management for Radiopharmaceuticals".

Wang Zhi, Executive Vice President of Quarkmed Imaging, delivered a keynote speech on "Hotspots in Nuclear Medicine R&D and Clinical Evaluation Models."

Li Zheng, President of Beijing United Imaging Intelligence Medical Imaging Technology Research Institute, presented a thematic sharing on "United Imaging Innovation Service Platform - Empowering Nuclear Medicine Research with Imaging Technology".

 

Round table discussion

Focusing on core topics such as the pain points and potential opportunities in nuclear medicine research and development, cutting-edge exploration of alpha radionuclide drugs, and other key issues, industry experts including Shi Jing, Chief Technology Officer & Global Clinical Business Head of InnoStar, Zhang Lan, General Manager of DeepView Therapeutics, Yuan Dawei, General Manager of Quarkmed, Zhou Yun, Chief Scientific Officer of United Imaging Research Institute, Liu Chuanwen, Partner of New Summit Capital, and Xie Fang, Research Fellow at Huashan Hospital Nuclear Medicine Department, gathered for a splendid roundtable discussion. Meanwhile, addressing audience concerns about alliance cooperation models, business development directions, and the application prospects of nuclear medicine, the experts provided detailed and insightful answers, presenting a wisdom feast in the field of nuclear medicine for the live audience.

The successful launch ceremony and forum conclusion of the VIQU Nuclear Medicine CXO Alliance not only marks the official initiation of this innovative alliance but also serves as a brilliant spark in China's nuclear medicine research field, continuously igniting and detonating deep reflections and heated discussions on the future development of nuclear medicine research. Alliance members will pool their innovative strengths to jointly drive technological breakthroughs in nuclear medicine research and clinical translation, establishing new models and benchmarks for nuclear medicine CRO services, and injecting unprecedented new vitality and vigor into China's nuclear medicine industry.

Regarding the VIQU Nuclear Medicine CXO Alliance

The Viqu Nuclear Medicine CXO Alliance was jointly initiated by DeepView Pharmaceuticals, Innovo Therapeutics, Quarkmed, and Shanghai United Imaging High-Tech Research Institute. The alliance aims to create a new one-stop service model for nuclear medicine through cross-enterprise complementary advantages and efficient cooperation, jointly promoting breakthroughs in nuclear medicine research and clinical translation technologies; strengthening technical collaboration to pool innovative forces in nuclear medicine technology, facilitating research and clinical translation of nuclear medicine technologies, and providing high-quality, rapid, and professional full-chain services for nuclear medicine research in China, empowering nuclear medicine innovation.